This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Magpie Trial Group | |
|---|---|
| Name | Magpie Trial Group |
| Type | Randomised controlled trial |
| Field | Obstetrics |
| Started | 1998 |
| Primary outcome | Maternal mortality and morbidity |
| Countries | United Kingdom; United States; Netherlands; India; China; Australia; Canada; South Africa; Norway; Sweden; Finland; Denmark; Japan; Italy; France; Germany; Spain; Portugal; Ireland; New Zealand |
Magpie Trial Group The Magpie Trial Group was a large international randomized controlled trial assessing the effects of Magnesium sulfate for the prevention of eclampsia in women with pre-eclampsia, initiated by investigators affiliated with institutions such as the Royal College of Obstetricians and Gynaecologists, World Health Organization, University of Oxford, Imperial College London and many national health services. The trial enrolled participants across centers in countries including the United Kingdom, United States, Netherlands, India, China, Australia, Canada and South Africa, aiming to inform clinical policy and guideline bodies like the National Institute for Health and Care Excellence and the Royal College of Physicians. Its outcomes influenced recommendations by organizations such as the World Health Organization and national ministries of health.
The trial emerged amid international debate after reports from landmark studies and case series from institutions such as Johns Hopkins Hospital, Hôpital Necker–Enfants Malades, Karolinska Institute, and Mayo Clinic suggested that Magnesium sulfate might reduce the incidence of eclampsia among women with pre-eclampsia, while alternative anticonvulsants like Diazepam, Phenytoin, and Sodium valproate were used in disparate protocols in settings including Nigeria, Kenya, Bangladesh, Pakistan, Indonesia and Philippines. Influential conferences at venues like World Congress of Perinatal Medicine and publications in journals such as The Lancet, The BMJ, and New England Journal of Medicine highlighted conflicting evidence from trials at centers such as John Radcliffe Hospital and St Thomas' Hospital, prompting the collaborative multicenter design endorsed by WHO and funded by agencies including the Medical Research Council (United Kingdom), Wellcome Trust, and national research councils.
The Magpie Trial Group employed a randomized, placebo-controlled, multicenter design with allocation concealment and intention-to-treat analysis, enrolling thousands of participants from tertiary referral centers like Addenbrooke's Hospital, Guy's Hospital, Queen Charlotte's and Chelsea Hospital, and community hospitals across continents. Trial governance involved data monitoring committees patterned after trials coordinated by Cochrane Collaboration, with statistical planning referencing methods from CONSORT and sample-size justification influenced by prior meta-analyses published by investigators linked to Cochrane Pregnancy and Childbirth Group. Collaborating research networks included academic units at University College London, Trinity College Dublin, University of Toronto, Karolinska Institute, University of Melbourne, and national trial registries analogous to ClinicalTrials.gov and the ISRCTN registry.
Participants diagnosed with pre-eclampsia received either Magnesium sulfate following a loading and maintenance regimen or a matching placebo, with dosing strategies informed by pharmacologic studies from laboratories at University of Oxford, Cambridge University, and pharmaceutical pharmacokinetic research from companies such as GlaxoSmithKline and Pfizer for safety comparison with anticonvulsants like Diazepam and Phenytoin. Clinical procedures for monitoring included maternal surveillance in high-dependency units at hospitals like Royal Infirmary of Edinburgh and fetal assessment using ultrasound protocols developed by groups at King's College Hospital and fetal medicine units at Helsinki University Hospital. Standardized case-report forms, consent procedures modeled after trials at Harvard Medical School and data collection templates similar to those used by the European Society of Paediatric and Neonatal Intensive Care ensured harmonization across sites.
Primary outcomes centered on maternal progression to eclampsia, maternal mortality, and serious maternal morbidity, with secondary outcomes addressing neonatal mortality, preterm birth, and intensive care admission, reported in major peer-reviewed outlets such as The Lancet and BMJ. The Magpie Trial Group found a significant reduction in progression to eclampsia with Magnesium sulfate compared with placebo, corroborating observational reports from centers like Johns Hopkins and systematic reviews by the Cochrane Collaboration. Subgroup analyses examined differences across regions including Europe, Asia, and Africa and across delivery contexts such as tertiary units and district hospitals exemplified by St George's Hospital and Groote Schuur Hospital.
Safety monitoring documented side effects and serious adverse events including respiratory depression and maternal cardiorespiratory compromise, with management algorithms paralleling protocols from Advanced Life Support in Obstetrics curricula and critical-care pathways used at Addenbrooke's Hospital and Royal Women's Hospital. Comparisons were made with adverse event profiles of anticonvulsants used in similar populations at institutions such as Mayo Clinic and Cleveland Clinic Foundation, and data informed risk–benefit assessments by agencies like the European Medicines Agency and national drug regulators.
Results from the trial influenced guideline revisions by bodies including the World Health Organization, Royal College of Obstetricians and Gynaecologists, American College of Obstetricians and Gynecologists, National Institute for Health and Care Excellence, and professional societies such as the International Federation of Gynecology and Obstetrics. Adoption of Magnesium sulfate prophylaxis expanded across perinatal networks in countries from United Kingdom and Ireland to India and South Africa, and was integrated into training programs at institutions like University of Oxford Medical School, Imperial College School of Medicine, and King's College London.
Critiques addressed generalizability to low-resource settings, dosing regimens, monitoring capacity, and cost-effectiveness compared with alternatives, prompting follow-up studies and implementation research at sites including University of Cape Town, All India Institute of Medical Sciences, Peking University First Hospital and randomized trials comparing regimens in networks coordinated by World Health Organization and funded by agencies such as the Bill & Melinda Gates Foundation. Subsequent meta-analyses by groups at Cochrane and secondary analyses published in BJOG and The Lancet Global Health explored long-term maternal and neurodevelopmental outcomes, health-systems integration, and policy uptake in diverse health systems like those of Norway, Sweden, Finland and low- and middle-income countries.
Category:Clinical trials in obstetrics